Test Price
2,800 AED✅ Home Collection Available
TARDBP Gene Amyotrophic Lateral Sclerosis Type 10 (ALS10) Genetic Test – NGS Analysis in UAE
Executive Summary & Core Metrics
- Diagnostic Accuracy: 99.9% analytical sensitivity for pathogenic variant detection across all coding exons and splice junctions.
- VIP Home Collection: Mobile phlebotomy with temperature-controlled cold-chain logistics, available daily from 8 AM to 11 PM.
- Post-Test Genetic Counseling: Telephone consultation with a board-certified medical geneticist for result interpretation.
- Insurance Verification: Direct coverage check via WhatsApp at +971545488731.
Test Overview & Methodology
The TARDBP NGS test provides comprehensive analysis of the TARDBP gene to detect pathogenic variants linked to Amyotrophic Lateral Sclerosis Type 10 (ALS10) — a heritable motor neuron disease. Next Generation Sequencing (NGS) technology enables simultaneous interrogation of all coding exons and flanking splice regions, delivering high-confidence variant calls with 99.9% analytical sensitivity.
| Feature | Our Test (TARDBP Full Gene NGS) | Closest Alternative (Targeted Mutation Panel) |
|---|---|---|
| Precision | 99.9% diagnostic sensitivity; full coding and splice regions | Limited to known hotspots, missing rare/novel variants |
| Method | Next Generation Sequencing (NGS) with bioinformatic confirmation | Sanger sequencing or restricted probe-based analysis |
| Turnaround Time | 3 to 4 Weeks | 3 to 4 Weeks (similar) |
Physician Insight & Safety Protocols
"As a Consultant Medical Genetics specializing in neurodegenerative disorders, I emphasize that TARDBP genetic testing must be correlated with full clinical evaluation, electromyography findings, and family pedigree analysis. A pathogenic variant confirms hereditary predisposition to ALS10, while a negative result does not exclude other genetic or sporadic motor neuron diseases. Pre-test and post-test genetic counseling by a board-certified medical geneticist is strongly recommended."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Clinical Advisory
Maintain all prescribed therapies, including riluzole, edaravone, or other supportive medications, unless explicitly instructed otherwise by your treating neurologist. Genetic information is intended to inform clinical care, not to replace ongoing medical management.
Safety Exclusion & Emergency Red Flags
- Exclusion Criteria: Test eligibility requires informed consent from the patient or legally authorized guardian. Acute systemic infection, uncontrolled bleeding diathesis, or inability to provide consent may defer collection.
- Emergency Warning: Sudden onset of respiratory distress, aspiration, choking, or loss of consciousness requires immediate emergency department evaluation. Do not delay emergency care for test results.
Patient FAQ & Clinical Guidance
1. What is the TARDBP Gene ALS Type 10 Test?
This test uses Next Generation Sequencing (NGS) to detect pathogenic mutations in the TARDBP gene, which is linked to familial amyotrophic lateral sclerosis type 10 (ALS10). It covers all coding exons and splice regions to identify single nucleotide variants and small insertions or deletions.
2. Who should consider this genetic test?
Individuals with a family history of ALS, early-onset motor weakness, or clinical suspicion of inherited motor neuron disease may benefit from this analysis. A referral from a neurologist or clinical geneticist is recommended prior to testing.
3. How accurate is the TARDBP NGS test for diagnosing ALS?
The analytical sensitivity exceeds 99.9% for single nucleotide variants and small insertions or deletions within the coding region and splice junctions. However, a negative result does not rule out other genetic or sporadic forms of ALS; clinical correlation remains essential.
UAE Regulatory & Data Privacy Adherence
Compliance Framework: This service operates in full adherence to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent follow Federal Decree-Law No. 4 of 2016 on Medical Liability. The laboratory is accredited to ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139). All sample handling and data processing comply with MOHAP and DHA standards.
Clinical & Logistical Metadata
| Test Name | TARDBP Gene Amyotrophic Lateral Sclerosis Type 10 (ALS10) Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood |
| Methodology Used | Next Generation Sequencing (NGS) |
| ICD-10-CM Code | G12.21 |
| LOINC Code | 96231-1 |
| DHA Facility License & Address | DHA License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians